Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ProMIS Neurosciences Inc. - Common Shares (NQ: PMN ) 1.250 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about ProMIS Neurosciences Inc. - Common Shares < Previous 1 2 Next > ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights August 08, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology August 06, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 August 01, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference July 30, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial July 26, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing July 26, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights May 14, 2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies April 30, 2024 Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS April 09, 2024 Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Present in Upcoming Investor Conferences in April April 04, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights April 01, 2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio March 11, 2024 Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference February 22, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine January 22, 2024 Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Issues Letter to Shareholders January 08, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences, Inc. Announces Leadership Transition January 03, 2024 Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Publication on Novel Target for ALS December 20, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease November 20, 2023 Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights November 14, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Closes $20.4 Million Private Placement Financing September 08, 2023 At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces $20.4 Million Private Placement Financing August 21, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights August 14, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease July 17, 2023 Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics Via Spotlight Growth ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline July 17, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Announces Completion of Continuance July 14, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange July 10, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved June 30, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time June 29, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights May 15, 2023 From ProMIS Neurosciences Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.